Brief: Arrowhead Expects Sarepta To Meet Financial Obligations Under License Agreement
23/07/2025 13:00
July 23 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O: ARROWHEAD PHARMACEUTICALS: EXPECTS SAREPTA TO CONTINUE TO MEET REQUIRED FINANCIAL OBLIGATIONS UNDER LICENSE AND COLLABORATION AGREEMENT ARROWHEAD PHARMACEUTICALS: IF SAREPTA FAILS TO MAKE $100 MILLION OR $200 MILLION NEAR-TERM PATIENT ENROLLMENT PAYMENT, CO WILL HAVE RIGHT TO TERMINATE AGREEMENT ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers